Data from Pharmawand - Curated by EPG Health - Date added 11 October 2017

Allergan plc announced that the FDA has accepted the New Drug Application (NDA) for ulipristal acetate, an investigational drug for the treatment of abnormal uterine bleeding in women with uterine fibroids. Allergan expects the ulipristal acetate Prescription Drug User Fee Act (PDUFA) action date to occur in the first half of 2018.

Comment: Ulipristal acetate, known as Esyma in the EU was approved to treat Uterine Fibroids in February 2013.

Comment:Forthcoming competition from AbbVie and Neurocrine Biosciences’ phase III elagolix is negatively influencing expectations for Esmya; First Order Analytics estimated a $286 million peak sales consensus which falls well below the $500 million to $1 billion range Allergan itself claimed.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more



See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more

Related Content